-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The study aimed to assess the progression of pulmonary function and chronic obstructive pulmonary disease (COPD) in patients with primary dryness syndrome (pSS), as well as the association between lung function, imaging performance, respiratory symptoms and pSS clinical characteristics, taking smoking into account.
40 pSS patients (average age 66 years old, ranging from 42-81 years old to 39 women) who had previously participated in the pSS lung-affected cross-sectional study re-evaluated lung function after an average of 6 years of follow-up.
follow-up, chest high-resolution CT (HRCT) and pSS disease activity, respiratory symptoms and smoking levels were also assessed.
pSS patients had a significant decrease in lung volume as a percentage of the expected value (TLC), residual gas volume (RV), RV/TLC ratio, and carbon monoxide dispersion capacity (DLCO), while the 1 second rate from baseline to follow-up (FEV1/VC) as a percentage of the expected value decreased significantly.
from baseline to follow-up, the proportion of COPD did not change significantly (38% vs.40%).
imaging signs of bronchal suffering and interstitirical pulmonary disease were found in 38 percent of patients.
and pulmonary diseases are common in patients with pSS, and obstructive and restrictive pulmonary dysfunction coexists, which worsens over time.
COPD is still common.
the pSS may be missed, special attention must be paid to the clinical evaluation of lung damage in pSS patients.
.
